Astragaloside IV, an active component isolated from *Astragalus membranaceus*, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells.
- Suppresses ERK1/2 and JNK activation
- Downregulates matrix metalloproteases (MMP)-2 and (MMP)-9
- Inhibits NSCLC cell growth and increases chemosensitivity to cisplatin
- Inhibits viability and invasive potential of MDA-MB-231 breast cancer cells
- Prevents cognitive deficits from cerebral ischemia and reperfusion
- Decreases cytokine levels and inhibits TLR4 pathways
- Attenuates NLRP3 and cleaved-caspase-1 expression
- Reduces serum ALT/AST levels and liver apoptosis
- Increases 48-hour survival rate in mice